Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Change in Receivables (2024 - 2025)

CG Oncology (CGON) has disclosed Change in Receivables for 2 consecutive years, with $301000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables fell 53.26% year-over-year to $301000.0, compared with a TTM value of $320000.0 through Dec 2025, changed N/A, and an annual FY2025 reading of $320000.0, down 53.56% over the prior year.
  • Change in Receivables was $301000.0 for Q4 2025 at CG Oncology, up from $238000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $644000.0 in Q4 2024 and bottomed at -$436000.0 in Q1 2025.